 [
    {
        "id": 5437,
        "drug_name": "OPDIVO (nivolumab) and YERVOY\u00a0(ipilimumab)",
        "clinical_trial_id": "NCT03215706",
        "has_trial_insight_page": 0,
        "indication": "First-line Non-small cell lung cancer (NSCLC)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-05-26",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20200526005870\/en\/",
        "note": "FDA Approval announced May 26, 2020.",
        "company_entity_id": 376,
        "company_ticker": "BMY",
        "company_name": "Bristol-Myers Squibb Company",
        "company_price": "54.4000",
        "company_change": 0.04,
        "company_percent_change": 0.07,
        "company_optionable": 1,
        "company_number_of_shares": 2022193411,
        "price_change_sparkline": [
            [
                48.87,
                1706677200
            ],
            [
                48.67,
                1706763600
            ],
            [
                48.71,
                1706850000
            ],
            [
                47.98,
                1707109200
            ],
            [
                49.26,
                1707195600
            ],
            [
                48.64,
                1707282000
            ],
            [
                48.71,
                1707368400
            ],
            [
                49.81,
                1707454800
            ],
            [
                49.75,
                1707714000
            ],
            [
                48.71,
                1707800400
            ],
            [
                48.89,
                1707886800
            ],
            [
                49.44,
                1707973200
            ],
            [
                49.86,
                1708059600
            ],
            [
                49.86,
                1708405200
            ],
            [
                50.91,
                1708491600
            ],
            [
                51.33,
                1708578000
            ],
            [
                51.66,
                1708664400
            ],
            [
                50.52,
                1708923600
            ],
            [
                50.51,
                1709010000
            ],
            [
                50.92,
                1709096400
            ],
            [
                50.75,
                1709182800
            ],
            [
                50.89,
                1709269200
            ],
            [
                50.92,
                1709528400
            ],
            [
                51.82,
                1709614800
            ],
            [
                53.38,
                1709701200
            ],
            [
                53.28,
                1709787600
            ],
            [
                53.79,
                1709874000
            ],
            [
                54.36,
                1710129600
            ],
            [
                54.4,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2737,
        "drug_name": "DUPIXENT (dupilumab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Atopic dermatitis 6-11 year-olds",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-05-26",
        "link": "https:\/\/investor.regeneron.com\/news-releases\/news-release-details\/fda-approves-dupixentr-dupilumab-first-biologic-medicine",
        "note": "FDA Approval announced May 26, 2020.",
        "company_entity_id": 388,
        "company_ticker": "REGN",
        "company_name": "Regeneron Pharmaceuticals Inc.",
        "company_price": "970.5700",
        "company_change": 6.13,
        "company_percent_change": 0.64,
        "company_optionable": 1,
        "company_number_of_shares": 109761896,
        "price_change_sparkline": [
            [
                942.78,
                1706677200
            ],
            [
                957.78,
                1706763600
            ],
            [
                945.18,
                1706850000
            ],
            [
                936.33,
                1707109200
            ],
            [
                937.81,
                1707195600
            ],
            [
                938.49,
                1707282000
            ],
            [
                946.43,
                1707368400
            ],
            [
                953.42,
                1707454800
            ],
            [
                947.06,
                1707714000
            ],
            [
                940.48,
                1707800400
            ],
            [
                947.82,
                1707886800
            ],
            [
                954.73,
                1707973200
            ],
            [
                948.05,
                1708059600
            ],
            [
                946.87,
                1708405200
            ],
            [
                952.84,
                1708491600
            ],
            [
                964.89,
                1708578000
            ],
            [
                981.2,
                1708664400
            ],
            [
                989.28,
                1708923600
            ],
            [
                993.35,
                1709010000
            ],
            [
                987.61,
                1709096400
            ],
            [
                966.09,
                1709182800
            ],
            [
                982.82,
                1709269200
            ],
            [
                971.19,
                1709528400
            ],
            [
                965.21,
                1709614800
            ],
            [
                972.1,
                1709701200
            ],
            [
                973.31,
                1709787600
            ],
            [
                968.83,
                1709874000
            ],
            [
                964.44,
                1710129600
            ],
            [
                970.57,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2737,
        "drug_name": "DUPIXENT (dupilumab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Atopic dermatitis 6-11 year-olds",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-05-26",
        "link": "https:\/\/investor.regeneron.com\/news-releases\/news-release-details\/fda-approves-dupixentr-dupilumab-first-biologic-medicine",
        "note": "FDA Approval announced May 26, 2020.",
        "company_entity_id": 389,
        "company_ticker": "SNY",
        "company_name": "Sanofi",
        "company_price": "48.4600",
        "company_change": 0.11,
        "company_percent_change": 0.23,
        "company_optionable": 1,
        "company_number_of_shares": 2529599938,
        "price_change_sparkline": [
            [
                49.9,
                1706677200
            ],
            [
                48.41,
                1706763600
            ],
            [
                47.23,
                1706850000
            ],
            [
                46.95,
                1707109200
            ],
            [
                47.06,
                1707195600
            ],
            [
                46.92,
                1707282000
            ],
            [
                46.56,
                1707368400
            ],
            [
                46.5,
                1707454800
            ],
            [
                46.34,
                1707714000
            ],
            [
                45.75,
                1707800400
            ],
            [
                45.8,
                1707886800
            ],
            [
                46.39,
                1707973200
            ],
            [
                46.18,
                1708059600
            ],
            [
                46.85,
                1708405200
            ],
            [
                47.92,
                1708491600
            ],
            [
                47.8,
                1708578000
            ],
            [
                48.77,
                1708664400
            ],
            [
                48.2,
                1708923600
            ],
            [
                48.21,
                1709010000
            ],
            [
                48,
                1709096400
            ],
            [
                47.85,
                1709182800
            ],
            [
                47.29,
                1709269200
            ],
            [
                47.15,
                1709528400
            ],
            [
                47.5,
                1709614800
            ],
            [
                47.68,
                1709701200
            ],
            [
                48.06,
                1709787600
            ],
            [
                48.25,
                1709874000
            ],
            [
                48.35,
                1710129600
            ],
            [
                48.46,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2866,
        "drug_name": "TAUVID (flortaucipir F 18 injection)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Patients evaluated for Alzheimer's Disease",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-05-28",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/lilly-receives-us-fda-approval-of-tauvid-flortaucipir-f-18-injection-for-use-in-patients-being-evaluated-for-alzheimers-disease-301067441.html",
        "note": "FDA Approval announced May 28, 2020.",
        "company_entity_id": 382,
        "company_ticker": "LLY",
        "company_name": "Eli Lilly and Company",
        "company_price": "754.9500",
        "company_change": 20.58,
        "company_percent_change": 2.8,
        "company_optionable": 1,
        "company_number_of_shares": 950164452,
        "price_change_sparkline": [
            [
                644.503643637706,
                1706677200
            ],
            [
                659.298247188938,
                1706763600
            ],
            [
                666.505874560051,
                1706850000
            ],
            [
                704.989812947364,
                1707109200
            ],
            [
                703.821817930162,
                1707195600
            ],
            [
                724.13694493877,
                1707282000
            ],
            [
                734.41929423551,
                1707368400
            ],
            [
                738.891617036422,
                1707454800
            ],
            [
                735.996586651903,
                1707714000
            ],
            [
                741.696801650387,
                1707800400
            ],
            [
                757.31,
                1707886800
            ],
            [
                757.78,
                1707973200
            ],
            [
                782.06,
                1708059600
            ],
            [
                755.66,
                1708405200
            ],
            [
                745.91,
                1708491600
            ],
            [
                769.64,
                1708578000
            ],
            [
                769.54,
                1708664400
            ],
            [
                771.92,
                1708923600
            ],
            [
                765,
                1709010000
            ],
            [
                757.64,
                1709096400
            ],
            [
                753.68,
                1709182800
            ],
            [
                782.12,
                1709269200
            ],
            [
                792.28,
                1709528400
            ],
            [
                777.59,
                1709614800
            ],
            [
                779.77,
                1709701200
            ],
            [
                780.16,
                1709787600
            ],
            [
                762.14,
                1709874000
            ],
            [
                734.37,
                1710129600
            ],
            [
                754.95,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4438,
        "drug_name": "CYRAMZA (ramucirumab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Non-small cell lung cancer",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-05-29",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/lillys-cyramza-ramucirumab-receives-fda-approval-as-first-line-treatment-for-metastatic-egfr-mutated-non-small-cell-lung-cancer-301068100.html",
        "note": "FDA Approval announced May 29, 2020.",
        "company_entity_id": 382,
        "company_ticker": "LLY",
        "company_name": "Eli Lilly and Company",
        "company_price": "754.9500",
        "company_change": 20.58,
        "company_percent_change": 2.8,
        "company_optionable": 1,
        "company_number_of_shares": 950164452,
        "price_change_sparkline": [
            [
                644.503643637706,
                1706677200
            ],
            [
                659.298247188938,
                1706763600
            ],
            [
                666.505874560051,
                1706850000
            ],
            [
                704.989812947364,
                1707109200
            ],
            [
                703.821817930162,
                1707195600
            ],
            [
                724.13694493877,
                1707282000
            ],
            [
                734.41929423551,
                1707368400
            ],
            [
                738.891617036422,
                1707454800
            ],
            [
                735.996586651903,
                1707714000
            ],
            [
                741.696801650387,
                1707800400
            ],
            [
                757.31,
                1707886800
            ],
            [
                757.78,
                1707973200
            ],
            [
                782.06,
                1708059600
            ],
            [
                755.66,
                1708405200
            ],
            [
                745.91,
                1708491600
            ],
            [
                769.64,
                1708578000
            ],
            [
                769.54,
                1708664400
            ],
            [
                771.92,
                1708923600
            ],
            [
                765,
                1709010000
            ],
            [
                757.64,
                1709096400
            ],
            [
                753.68,
                1709182800
            ],
            [
                782.12,
                1709269200
            ],
            [
                792.28,
                1709528400
            ],
            [
                777.59,
                1709614800
            ],
            [
                779.77,
                1709701200
            ],
            [
                780.16,
                1709787600
            ],
            [
                762.14,
                1709874000
            ],
            [
                734.37,
                1710129600
            ],
            [
                754.95,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3535,
        "drug_name": "ZILXI (FMX103)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Papulopustular rosacea",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-05-29",
        "link": "https:\/\/menlotherapeutics.gcs-web.com\/news-releases\/news-release-details\/menlo-therapeutics-receives-fda-approval-zilxitm-minocycline",
        "note": "FDA Approval announced May 29, 2020.",
        "company_entity_id": 875,
        "company_ticker": "VYNE",
        "company_name": "VYNE Therapeutics Inc.",
        "company_price": "2.1000",
        "company_change": -0.040000000000000036,
        "company_percent_change": -1.87,
        "company_optionable": 0,
        "company_number_of_shares": 14098888,
        "price_change_sparkline": [
            [
                1.71,
                1706677200
            ],
            [
                1.82,
                1706763600
            ],
            [
                1.9,
                1706850000
            ],
            [
                2.1,
                1707109200
            ],
            [
                2.11,
                1707195600
            ],
            [
                2.15,
                1707282000
            ],
            [
                2.14,
                1707368400
            ],
            [
                2.14,
                1707454800
            ],
            [
                2.07,
                1707714000
            ],
            [
                2.01,
                1707800400
            ],
            [
                2.07,
                1707886800
            ],
            [
                2.16,
                1707973200
            ],
            [
                2.27,
                1708059600
            ],
            [
                2.23,
                1708405200
            ],
            [
                2.17,
                1708491600
            ],
            [
                2.17,
                1708578000
            ],
            [
                2.26,
                1708664400
            ],
            [
                2.35,
                1708923600
            ],
            [
                2.37,
                1709010000
            ],
            [
                2.33,
                1709096400
            ],
            [
                2.23,
                1709182800
            ],
            [
                2.22,
                1709269200
            ],
            [
                2.28,
                1709528400
            ],
            [
                2.25,
                1709614800
            ],
            [
                2.35,
                1709701200
            ],
            [
                2.32,
                1709787600
            ],
            [
                2.245,
                1709874000
            ],
            [
                2.14,
                1710129600
            ],
            [
                2.1,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5451,
        "drug_name": "TECENTRIQ (atezolizumab) + AVASTIN (Bevacizumab) - IMbrave 150",
        "clinical_trial_id": "NCT03434379",
        "has_trial_insight_page": 0,
        "indication": "Hepatocellular carcinoma",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-05-29",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20200529005593\/en\/",
        "note": "FDA Approval announced May 29, 2020.",
        "company_entity_id": 536,
        "company_ticker": "RHHBY",
        "company_name": "Roche Holding AG ADR",
        "company_price": "35.1500",
        "company_change": 0.54,
        "company_percent_change": 1.56,
        "company_optionable": 0,
        "company_number_of_shares": 6389213336,
        "price_change_sparkline": [
            [
                35.14,
                1706677200
            ],
            [
                34.32,
                1706763600
            ],
            [
                33.95,
                1706850000
            ],
            [
                33.16,
                1707109200
            ],
            [
                33.27,
                1707195600
            ],
            [
                32.55,
                1707282000
            ],
            [
                32.1,
                1707368400
            ],
            [
                32.31,
                1707454800
            ],
            [
                32.6,
                1707714000
            ],
            [
                32.13,
                1707800400
            ],
            [
                32.02,
                1707886800
            ],
            [
                32.1,
                1707973200
            ],
            [
                32.28,
                1708059600
            ],
            [
                32.74,
                1708405200
            ],
            [
                32.91,
                1708491600
            ],
            [
                32.49,
                1708578000
            ],
            [
                32.96,
                1708664400
            ],
            [
                32.52,
                1708923600
            ],
            [
                33.03,
                1709010000
            ],
            [
                32.93,
                1709096400
            ],
            [
                32.73,
                1709182800
            ],
            [
                33.08,
                1709269200
            ],
            [
                32.88,
                1709528400
            ],
            [
                33.15,
                1709614800
            ],
            [
                33.47,
                1709701200
            ],
            [
                33.77,
                1709787600
            ],
            [
                33.9,
                1709874000
            ],
            [
                34.61,
                1710129600
            ],
            [
                35.15,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3654,
        "drug_name": "ORILISSA (Elagolix)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Uterine Fibroids",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-05-29",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/fda-approves-the-first-oral-medication-for-the-management-of-heavy-menstrual-bleeding-due-to-uterine-fibroids-in-pre-menopausal-women-301067963.html",
        "note": "FDA approval announced May 29, 2020.",
        "company_entity_id": 369,
        "company_ticker": "ABBV",
        "company_name": "AbbVie Inc.",
        "company_price": "180.9200",
        "company_change": 1.29,
        "company_percent_change": 0.72,
        "company_optionable": 1,
        "company_number_of_shares": 1766473359,
        "price_change_sparkline": [
            [
                164.4,
                1706677200
            ],
            [
                167.59,
                1706763600
            ],
            [
                168.67,
                1706850000
            ],
            [
                171.26,
                1707109200
            ],
            [
                173.29,
                1707195600
            ],
            [
                175.01,
                1707282000
            ],
            [
                174.79,
                1707368400
            ],
            [
                174.08,
                1707454800
            ],
            [
                173.07,
                1707714000
            ],
            [
                173.29,
                1707800400
            ],
            [
                174.42,
                1707886800
            ],
            [
                176.59,
                1707973200
            ],
            [
                177.49,
                1708059600
            ],
            [
                175.75,
                1708405200
            ],
            [
                175.14,
                1708491600
            ],
            [
                176.75,
                1708578000
            ],
            [
                178.09,
                1708664400
            ],
            [
                178.81,
                1708923600
            ],
            [
                178.99,
                1709010000
            ],
            [
                178,
                1709096400
            ],
            [
                176.05,
                1709182800
            ],
            [
                178.91,
                1709269200
            ],
            [
                177.05,
                1709528400
            ],
            [
                179.16,
                1709614800
            ],
            [
                181.06,
                1709701200
            ],
            [
                180.57,
                1709787600
            ],
            [
                178.85,
                1709874000
            ],
            [
                179.63,
                1710129600
            ],
            [
                180.92,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3654,
        "drug_name": "ORILISSA (Elagolix)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Uterine Fibroids",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-05-29",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/fda-approves-the-first-oral-medication-for-the-management-of-heavy-menstrual-bleeding-due-to-uterine-fibroids-in-pre-menopausal-women-301067963.html",
        "note": "FDA approval announced May 29, 2020.",
        "company_entity_id": 205,
        "company_ticker": "NBIX",
        "company_name": "Neurocrine Biosciences Inc.",
        "company_price": "137.7400",
        "company_change": -0.87,
        "company_percent_change": -0.63,
        "company_optionable": 1,
        "company_number_of_shares": 99507490,
        "price_change_sparkline": [
            [
                139.77,
                1706677200
            ],
            [
                142.45,
                1706763600
            ],
            [
                141.74,
                1706850000
            ],
            [
                141.66,
                1707109200
            ],
            [
                142.96,
                1707195600
            ],
            [
                136.29,
                1707282000
            ],
            [
                134.42,
                1707368400
            ],
            [
                132.3,
                1707454800
            ],
            [
                130.43,
                1707714000
            ],
            [
                133.84,
                1707800400
            ],
            [
                131.77,
                1707886800
            ],
            [
                134,
                1707973200
            ],
            [
                132.31,
                1708059600
            ],
            [
                132.65,
                1708405200
            ],
            [
                130.65,
                1708491600
            ],
            [
                133.37,
                1708578000
            ],
            [
                134.18,
                1708664400
            ],
            [
                135.58,
                1708923600
            ],
            [
                136.03,
                1709010000
            ],
            [
                134.66,
                1709096400
            ],
            [
                130.4,
                1709182800
            ],
            [
                131.3,
                1709269200
            ],
            [
                133.12,
                1709528400
            ],
            [
                133.67,
                1709614800
            ],
            [
                132.25,
                1709701200
            ],
            [
                135.33,
                1709787600
            ],
            [
                139.22,
                1709874000
            ],
            [
                138.61,
                1710129600
            ],
            [
                137.74,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5475,
        "drug_name": "TALTZ (ixekizumab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Non-radiographic axial spondyloarthritis",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-06-01",
        "link": "https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lillys-taltzr-ixekizumab-first-il-17a-antagonist-receive-us-fda",
        "note": "FDA Approval announced June 1, 2020.",
        "company_entity_id": 382,
        "company_ticker": "LLY",
        "company_name": "Eli Lilly and Company",
        "company_price": "754.9500",
        "company_change": 20.58,
        "company_percent_change": 2.8,
        "company_optionable": 1,
        "company_number_of_shares": 950164452,
        "price_change_sparkline": [
            [
                644.503643637706,
                1706677200
            ],
            [
                659.298247188938,
                1706763600
            ],
            [
                666.505874560051,
                1706850000
            ],
            [
                704.989812947364,
                1707109200
            ],
            [
                703.821817930162,
                1707195600
            ],
            [
                724.13694493877,
                1707282000
            ],
            [
                734.41929423551,
                1707368400
            ],
            [
                738.891617036422,
                1707454800
            ],
            [
                735.996586651903,
                1707714000
            ],
            [
                741.696801650387,
                1707800400
            ],
            [
                757.31,
                1707886800
            ],
            [
                757.78,
                1707973200
            ],
            [
                782.06,
                1708059600
            ],
            [
                755.66,
                1708405200
            ],
            [
                745.91,
                1708491600
            ],
            [
                769.64,
                1708578000
            ],
            [
                769.54,
                1708664400
            ],
            [
                771.92,
                1708923600
            ],
            [
                765,
                1709010000
            ],
            [
                757.64,
                1709096400
            ],
            [
                753.68,
                1709182800
            ],
            [
                782.12,
                1709269200
            ],
            [
                792.28,
                1709528400
            ],
            [
                777.59,
                1709614800
            ],
            [
                779.77,
                1709701200
            ],
            [
                780.16,
                1709787600
            ],
            [
                762.14,
                1709874000
            ],
            [
                734.37,
                1710129600
            ],
            [
                754.95,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2982,
        "drug_name": "BRILINTA (ticagrelor) - (THEMIS)",
        "clinical_trial_id": "NCT01991795",
        "has_trial_insight_page": 0,
        "indication": "Type 2 Diabetes \/ coronary artery disease (CAD)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-06-01",
        "link": "https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2020\/brilinta-approved-in-the-us-to-reduce-the-risk-of-a-first-heart-attack-or-stroke-in-high-risk-patients-with-coronary-artery-disease.html",
        "note": "FDA approval announced June 1, 2020.",
        "company_entity_id": 374,
        "company_ticker": "AZN",
        "company_name": "AstraZeneca PLC",
        "company_price": "67.4000",
        "company_change": -0.27,
        "company_percent_change": -0.4,
        "company_optionable": 1,
        "company_number_of_shares": 3100378676,
        "price_change_sparkline": [
            [
                65.6319311986485,
                1706677200
            ],
            [
                65.8387545112493,
                1706763600
            ],
            [
                64.647058281502,
                1706850000
            ],
            [
                64.1546218229287,
                1707109200
            ],
            [
                66.0258803655072,
                1707195600
            ],
            [
                65.5432926361053,
                1707282000
            ],
            [
                62.5591276971512,
                1707368400
            ],
            [
                61.3181878215465,
                1707454800
            ],
            [
                60.4810458419719,
                1707714000
            ],
            [
                60.1067941334562,
                1707800400
            ],
            [
                60.7272640712585,
                1707886800
            ],
            [
                61.8894141134915,
                1707973200
            ],
            [
                63.2977823850111,
                1708059600
            ],
            [
                64.056134531214,
                1708405200
            ],
            [
                64.1053781770713,
                1708491600
            ],
            [
                64.13,
                1708578000
            ],
            [
                65.83,
                1708664400
            ],
            [
                65.93,
                1708923600
            ],
            [
                66.33,
                1709010000
            ],
            [
                65.35,
                1709096400
            ],
            [
                64.16,
                1709182800
            ],
            [
                64.6,
                1709269200
            ],
            [
                64.79,
                1709528400
            ],
            [
                64.81,
                1709614800
            ],
            [
                65.27,
                1709701200
            ],
            [
                66.19,
                1709787600
            ],
            [
                66.5,
                1709874000
            ],
            [
                67.67,
                1710129600
            ],
            [
                67.4,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6375,
        "drug_name": "RECARBRIO (imipenem, cilastatin, and relebactam)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP\/VABP)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-06-04",
        "link": "https:\/\/investors.merck.com\/news\/press-release-details\/2020\/FDA-Approves-Mercks-RECARBRIO-imipenem-cilastatin-and-relebactam-for-the-Treatment-of-Adults-with-Hospital-Acquired-and-Ventilator-Associated-Bacterial-Pneumonia-HABPVABP\/default.aspx",
        "note": "FDA approval announced June 4, 2020.",
        "company_entity_id": 383,
        "company_ticker": "MRK",
        "company_name": "Merck & Company Inc.",
        "company_price": "122.6600",
        "company_change": -0.10999999999999999,
        "company_percent_change": -0.08999999999999997,
        "company_optionable": 1,
        "company_number_of_shares": 2532643872,
        "price_change_sparkline": [
            [
                120.78,
                1706677200
            ],
            [
                126.38,
                1706763600
            ],
            [
                126.41,
                1706850000
            ],
            [
                126.18,
                1707109200
            ],
            [
                126.88,
                1707195600
            ],
            [
                127.47,
                1707282000
            ],
            [
                126.61,
                1707368400
            ],
            [
                125.45,
                1707454800
            ],
            [
                125.34,
                1707714000
            ],
            [
                125.43,
                1707800400
            ],
            [
                125.82,
                1707886800
            ],
            [
                126.54,
                1707973200
            ],
            [
                127.79,
                1708059600
            ],
            [
                127.37,
                1708405200
            ],
            [
                128.12,
                1708491600
            ],
            [
                129.26,
                1708578000
            ],
            [
                129.45,
                1708664400
            ],
            [
                128.84,
                1708923600
            ],
            [
                129.03,
                1709010000
            ],
            [
                128.19,
                1709096400
            ],
            [
                127.15,
                1709182800
            ],
            [
                126.96,
                1709269200
            ],
            [
                124.05,
                1709528400
            ],
            [
                122.83,
                1709614800
            ],
            [
                123.75,
                1709701200
            ],
            [
                123.99,
                1709787600
            ],
            [
                123.5,
                1709874000
            ],
            [
                122.77,
                1710129600
            ],
            [
                122.66,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6105,
        "drug_name": "UPLIZNA (Inebilizumab)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Neuromyelitis Optica Spectrum Disorder",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-06-11",
        "link": "https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-therapy-rare-disease-affecting-optic-nerve-spinal-cord",
        "note": "FDA Approval announced June 11, 2020.",
        "company_entity_id": 372,
        "company_ticker": "AMGN",
        "company_name": "Amgen Inc.",
        "company_price": "276.5400",
        "company_change": 1.18,
        "company_percent_change": 0.43,
        "company_optionable": 1,
        "company_number_of_shares": 535918901,
        "price_change_sparkline": [
            [
                311.832823699025,
                1706677200
            ],
            [
                322.053272003295,
                1706763600
            ],
            [
                320.693853151174,
                1706850000
            ],
            [
                319.483275779212,
                1707109200
            ],
            [
                313.62884422628,
                1707195600
            ],
            [
                293.584858231498,
                1707282000
            ],
            [
                292.572736166415,
                1707368400
            ],
            [
                288.871544693121,
                1707454800
            ],
            [
                292.155980021969,
                1707714000
            ],
            [
                288.236487711108,
                1707800400
            ],
            [
                287.829654332006,
                1707886800
            ],
            [
                289.07,
                1707973200
            ],
            [
                283.7,
                1708059600
            ],
            [
                283.51,
                1708405200
            ],
            [
                283.46,
                1708491600
            ],
            [
                285.18,
                1708578000
            ],
            [
                289.18,
                1708664400
            ],
            [
                286.37,
                1708923600
            ],
            [
                278.49,
                1709010000
            ],
            [
                277.46,
                1709096400
            ],
            [
                273.83,
                1709182800
            ],
            [
                280.33,
                1709269200
            ],
            [
                279.39,
                1709528400
            ],
            [
                276.65,
                1709614800
            ],
            [
                276.59,
                1709701200
            ],
            [
                272.86,
                1709787600
            ],
            [
                273.75,
                1709874000
            ],
            [
                275.36,
                1710129600
            ],
            [
                276.54,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6727,
        "drug_name": "GARDASIL 9",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Prevention HPV-Related Head and Neck Cancers",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-06-12",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20200612005599\/en\/",
        "note": "FDA Approval announced June 12, 2020.",
        "company_entity_id": 383,
        "company_ticker": "MRK",
        "company_name": "Merck & Company Inc.",
        "company_price": "122.6600",
        "company_change": -0.10999999999999999,
        "company_percent_change": -0.08999999999999997,
        "company_optionable": 1,
        "company_number_of_shares": 2532643872,
        "price_change_sparkline": [
            [
                120.78,
                1706677200
            ],
            [
                126.38,
                1706763600
            ],
            [
                126.41,
                1706850000
            ],
            [
                126.18,
                1707109200
            ],
            [
                126.88,
                1707195600
            ],
            [
                127.47,
                1707282000
            ],
            [
                126.61,
                1707368400
            ],
            [
                125.45,
                1707454800
            ],
            [
                125.34,
                1707714000
            ],
            [
                125.43,
                1707800400
            ],
            [
                125.82,
                1707886800
            ],
            [
                126.54,
                1707973200
            ],
            [
                127.79,
                1708059600
            ],
            [
                127.37,
                1708405200
            ],
            [
                128.12,
                1708491600
            ],
            [
                129.26,
                1708578000
            ],
            [
                129.45,
                1708664400
            ],
            [
                128.84,
                1708923600
            ],
            [
                129.03,
                1709010000
            ],
            [
                128.19,
                1709096400
            ],
            [
                127.15,
                1709182800
            ],
            [
                126.96,
                1709269200
            ],
            [
                124.05,
                1709528400
            ],
            [
                122.83,
                1709614800
            ],
            [
                123.75,
                1709701200
            ],
            [
                123.99,
                1709787600
            ],
            [
                123.5,
                1709874000
            ],
            [
                122.77,
                1710129600
            ],
            [
                122.66,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2859,
        "drug_name": "LYUMJEV (ultra rapid insulin)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Diabetes",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-06-15",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/fda-approves-lyumjev-insulin-lispro-aabc-injection-lillys-new-rapid-acting-insulin-301077294.html",
        "note": "FDA Approval announced June 15, 2020.",
        "company_entity_id": 382,
        "company_ticker": "LLY",
        "company_name": "Eli Lilly and Company",
        "company_price": "754.9500",
        "company_change": 20.58,
        "company_percent_change": 2.8,
        "company_optionable": 1,
        "company_number_of_shares": 950164452,
        "price_change_sparkline": [
            [
                644.503643637706,
                1706677200
            ],
            [
                659.298247188938,
                1706763600
            ],
            [
                666.505874560051,
                1706850000
            ],
            [
                704.989812947364,
                1707109200
            ],
            [
                703.821817930162,
                1707195600
            ],
            [
                724.13694493877,
                1707282000
            ],
            [
                734.41929423551,
                1707368400
            ],
            [
                738.891617036422,
                1707454800
            ],
            [
                735.996586651903,
                1707714000
            ],
            [
                741.696801650387,
                1707800400
            ],
            [
                757.31,
                1707886800
            ],
            [
                757.78,
                1707973200
            ],
            [
                782.06,
                1708059600
            ],
            [
                755.66,
                1708405200
            ],
            [
                745.91,
                1708491600
            ],
            [
                769.64,
                1708578000
            ],
            [
                769.54,
                1708664400
            ],
            [
                771.92,
                1708923600
            ],
            [
                765,
                1709010000
            ],
            [
                757.64,
                1709096400
            ],
            [
                753.68,
                1709182800
            ],
            [
                782.12,
                1709269200
            ],
            [
                792.28,
                1709528400
            ],
            [
                777.59,
                1709614800
            ],
            [
                779.77,
                1709701200
            ],
            [
                780.16,
                1709787600
            ],
            [
                762.14,
                1709874000
            ],
            [
                734.37,
                1710129600
            ],
            [
                754.95,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6277,
        "drug_name": "ZEPZELCA (lurbinectedin)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Small cell lung cancer (SCLC)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-06-15",
        "link": "http:\/\/investor.jazzpharma.com\/news-releases\/news-release-details\/jazz-pharmaceuticals-announces-us-fda-accelerated-approval",
        "note": "FDA Approval announced June 15, 2020.",
        "company_entity_id": 381,
        "company_ticker": "JAZZ",
        "company_name": "Jazz Pharmaceuticals plc",
        "company_price": "115.7900",
        "company_change": -0.84,
        "company_percent_change": -0.72,
        "company_optionable": 1,
        "company_number_of_shares": 62345283,
        "price_change_sparkline": [
            [
                122.72,
                1706677200
            ],
            [
                123.68,
                1706763600
            ],
            [
                122.9,
                1706850000
            ],
            [
                121.98,
                1707109200
            ],
            [
                124.71,
                1707195600
            ],
            [
                122.94,
                1707282000
            ],
            [
                122.67,
                1707368400
            ],
            [
                123.43,
                1707454800
            ],
            [
                124.24,
                1707714000
            ],
            [
                121.83,
                1707800400
            ],
            [
                122.24,
                1707886800
            ],
            [
                126.82,
                1707973200
            ],
            [
                126.78,
                1708059600
            ],
            [
                126.36,
                1708405200
            ],
            [
                128.42,
                1708491600
            ],
            [
                128.45,
                1708578000
            ],
            [
                132.28,
                1708664400
            ],
            [
                132.77,
                1708923600
            ],
            [
                132.26,
                1709010000
            ],
            [
                129.7,
                1709096400
            ],
            [
                118.9,
                1709182800
            ],
            [
                118.85,
                1709269200
            ],
            [
                117.53,
                1709528400
            ],
            [
                118.42,
                1709614800
            ],
            [
                117.19,
                1709701200
            ],
            [
                116.37,
                1709787600
            ],
            [
                117.53,
                1709874000
            ],
            [
                116.63,
                1710129600
            ],
            [
                115.79,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6732,
        "drug_name": "JUV\u00c9DERM VOLUMA",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Augmentation of the chin region",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-06-15",
        "link": "https:\/\/news.abbvie.com\/news\/press-releases\/fda-approves-juvderm-voluma-xc-for-enhancement-chin-region.htm?view_id=822",
        "note": "FDA Approval announced June 15, 2020.",
        "company_entity_id": 369,
        "company_ticker": "ABBV",
        "company_name": "AbbVie Inc.",
        "company_price": "180.9200",
        "company_change": 1.29,
        "company_percent_change": 0.72,
        "company_optionable": 1,
        "company_number_of_shares": 1766473359,
        "price_change_sparkline": [
            [
                164.4,
                1706677200
            ],
            [
                167.59,
                1706763600
            ],
            [
                168.67,
                1706850000
            ],
            [
                171.26,
                1707109200
            ],
            [
                173.29,
                1707195600
            ],
            [
                175.01,
                1707282000
            ],
            [
                174.79,
                1707368400
            ],
            [
                174.08,
                1707454800
            ],
            [
                173.07,
                1707714000
            ],
            [
                173.29,
                1707800400
            ],
            [
                174.42,
                1707886800
            ],
            [
                176.59,
                1707973200
            ],
            [
                177.49,
                1708059600
            ],
            [
                175.75,
                1708405200
            ],
            [
                175.14,
                1708491600
            ],
            [
                176.75,
                1708578000
            ],
            [
                178.09,
                1708664400
            ],
            [
                178.81,
                1708923600
            ],
            [
                178.99,
                1709010000
            ],
            [
                178,
                1709096400
            ],
            [
                176.05,
                1709182800
            ],
            [
                178.91,
                1709269200
            ],
            [
                177.05,
                1709528400
            ],
            [
                179.16,
                1709614800
            ],
            [
                181.06,
                1709701200
            ],
            [
                180.57,
                1709787600
            ],
            [
                178.85,
                1709874000
            ],
            [
                179.63,
                1710129600
            ],
            [
                180.92,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5447,
        "drug_name": "COSENTYX (secukinumab) - PREVENT",
        "clinical_trial_id": "NCT02696031",
        "has_trial_insight_page": 0,
        "indication": "Non-radiographic axial spondyloarthritis",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-06-16",
        "link": "https:\/\/ml-eu.globenewswire.com\/Resource\/Download\/84c080cf-8270-447f-8b20-a94e4076385e",
        "note": "FDA Approval announced June 16, 2020.",
        "company_entity_id": 386,
        "company_ticker": "NVS",
        "company_name": "Novartis AG",
        "company_price": "99.7700",
        "company_change": -1.6,
        "company_percent_change": -1.58,
        "company_optionable": 1,
        "company_number_of_shares": 2044033986,
        "price_change_sparkline": [
            [
                99.701426650332,
                1706677200
            ],
            [
                101.493681927897,
                1706763600
            ],
            [
                99.9423211768864,
                1706850000
            ],
            [
                99.701426650332,
                1707109200
            ],
            [
                99.9615927390107,
                1707195600
            ],
            [
                99.6917908692698,
                1707282000
            ],
            [
                97.6682768462129,
                1707368400
            ],
            [
                97.3502960711611,
                1707454800
            ],
            [
                96.8685070180523,
                1707714000
            ],
            [
                95.4520472019125,
                1707800400
            ],
            [
                95.4424114208503,
                1707886800
            ],
            [
                96.0012867224565,
                1707973200
            ],
            [
                96.5408904619384,
                1708059600
            ],
            [
                98.9787430706688,
                1708405200
            ],
            [
                98.824570573674,
                1708491600
            ],
            [
                99.0558293191662,
                1708578000
            ],
            [
                100.115765236006,
                1708664400
            ],
            [
                99.4894394669641,
                1708923600
            ],
            [
                99.3930816563424,
                1709010000
            ],
            [
                98.49695401756,
                1709096400
            ],
            [
                97.2924813847881,
                1709182800
            ],
            [
                98.3427815205652,
                1709269200
            ],
            [
                98.2560594910056,
                1709528400
            ],
            [
                98.3813246448139,
                1709614800
            ],
            [
                98.9016568221714,
                1709701200
            ],
            [
                99.93,
                1709787600
            ],
            [
                100.71,
                1709874000
            ],
            [
                101.37,
                1710129600
            ],
            [
                99.77,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6555,
        "drug_name": "KEYTRUDA (pembrolizumab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Solid tumors - TMB-H \u226510 mutations\/megabase",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-06-17",
        "link": "https:\/\/investors.merck.com\/news\/press-release-details\/2020\/FDA-Approves-Second-Biomarker-Based-Indication-for-Mercks-KEYTRUDA-pembrolizumab-Regardless-of-Tumor-Type\/default.aspx",
        "note": "FDA Approval June 17, 2020.",
        "company_entity_id": 383,
        "company_ticker": "MRK",
        "company_name": "Merck & Company Inc.",
        "company_price": "122.6600",
        "company_change": -0.10999999999999999,
        "company_percent_change": -0.08999999999999997,
        "company_optionable": 1,
        "company_number_of_shares": 2532643872,
        "price_change_sparkline": [
            [
                120.78,
                1706677200
            ],
            [
                126.38,
                1706763600
            ],
            [
                126.41,
                1706850000
            ],
            [
                126.18,
                1707109200
            ],
            [
                126.88,
                1707195600
            ],
            [
                127.47,
                1707282000
            ],
            [
                126.61,
                1707368400
            ],
            [
                125.45,
                1707454800
            ],
            [
                125.34,
                1707714000
            ],
            [
                125.43,
                1707800400
            ],
            [
                125.82,
                1707886800
            ],
            [
                126.54,
                1707973200
            ],
            [
                127.79,
                1708059600
            ],
            [
                127.37,
                1708405200
            ],
            [
                128.12,
                1708491600
            ],
            [
                129.26,
                1708578000
            ],
            [
                129.45,
                1708664400
            ],
            [
                128.84,
                1708923600
            ],
            [
                129.03,
                1709010000
            ],
            [
                128.19,
                1709096400
            ],
            [
                127.15,
                1709182800
            ],
            [
                126.96,
                1709269200
            ],
            [
                124.05,
                1709528400
            ],
            [
                122.83,
                1709614800
            ],
            [
                123.75,
                1709701200
            ],
            [
                123.99,
                1709787600
            ],
            [
                123.5,
                1709874000
            ],
            [
                122.77,
                1710129600
            ],
            [
                122.66,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4072,
        "drug_name": "TAZVERIK (Tazemetostat)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Follicular lymphoma",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-06-18",
        "link": "https:\/\/epizyme.gcs-web.com\/news-releases\/news-release-details\/epizyme-announces-us-fda-accelerated-approval-tazveriktm-0",
        "note": "FDA approval announced June 18, 2020.",
        "company_entity_id": 132,
        "company_ticker": "EPZM",
        "company_name": "Epizyme Inc.",
        "company_price": "1.4700",
        "company_change": 0,
        "company_percent_change": 0,
        "company_optionable": 0,
        "company_number_of_shares": 168364752,
        "statuses": []
    },
    {
        "id": 3988,
        "drug_name": "CRYSVITA (burosumab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Tumor-induced osteomalacia (TIO)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-06-18",
        "link": "http:\/\/ir.ultragenyx.com\/news-releases\/news-release-details\/ultragenyx-and-kyowa-kirin-announce-us-fda-approval-crysvitar",
        "note": "FDA Approval announced June 18, 2020.",
        "company_entity_id": 258,
        "company_ticker": "RARE",
        "company_name": "Ultragenyx Pharmaceutical Inc.",
        "company_price": "47.6600",
        "company_change": -0.85,
        "company_percent_change": -1.75,
        "company_optionable": 1,
        "company_number_of_shares": 82335687,
        "price_change_sparkline": [
            [
                44.11,
                1706677200
            ],
            [
                44.1,
                1706763600
            ],
            [
                43.02,
                1706850000
            ],
            [
                44.76,
                1707109200
            ],
            [
                45.89,
                1707195600
            ],
            [
                44.71,
                1707282000
            ],
            [
                45.45,
                1707368400
            ],
            [
                46.73,
                1707454800
            ],
            [
                46.74,
                1707714000
            ],
            [
                43.98,
                1707800400
            ],
            [
                45.66,
                1707886800
            ],
            [
                46.26,
                1707973200
            ],
            [
                48.92,
                1708059600
            ],
            [
                47.87,
                1708405200
            ],
            [
                48.18,
                1708491600
            ],
            [
                48.88,
                1708578000
            ],
            [
                49.48,
                1708664400
            ],
            [
                50.25,
                1708923600
            ],
            [
                53.66,
                1709010000
            ],
            [
                52.75,
                1709096400
            ],
            [
                51.72,
                1709182800
            ],
            [
                53.69,
                1709269200
            ],
            [
                53.31,
                1709528400
            ],
            [
                51.47,
                1709614800
            ],
            [
                51.26,
                1709701200
            ],
            [
                50.85,
                1709787600
            ],
            [
                50.53,
                1709874000
            ],
            [
                48.51,
                1710129600
            ],
            [
                47.66,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3515,
        "drug_name": "GIMOTI (metoclopramide)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Diabetic gastroparesis",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-06-19",
        "link": "https:\/\/evokepharmainc.gcs-web.com\/news-releases\/news-release-details\/fda-approves-evokes-gimotitm",
        "note": "FDA Approval announced June 19, 2020.",
        "company_entity_id": 135,
        "company_ticker": "EVOK",
        "company_name": "Evoke Pharma Inc.",
        "company_price": "0.6500",
        "company_change": -0.010000000000000009,
        "company_percent_change": -0.76,
        "company_optionable": 0,
        "company_number_of_shares": 3343070,
        "price_change_sparkline": [
            [
                0.68,
                1706677200
            ],
            [
                0.671,
                1706763600
            ],
            [
                0.7005,
                1706850000
            ],
            [
                0.68,
                1707109200
            ],
            [
                0.75,
                1707195600
            ],
            [
                0.6515,
                1707282000
            ],
            [
                0.6425,
                1707368400
            ],
            [
                0.745,
                1707454800
            ],
            [
                0.691,
                1707714000
            ],
            [
                0.6737,
                1707800400
            ],
            [
                0.70625,
                1707886800
            ],
            [
                0.7,
                1707973200
            ],
            [
                0.68,
                1708059600
            ],
            [
                0.6899,
                1708405200
            ],
            [
                0.679,
                1708491600
            ],
            [
                0.669,
                1708578000
            ],
            [
                0.6411,
                1708664400
            ],
            [
                0.6299,
                1708923600
            ],
            [
                0.6307,
                1709010000
            ],
            [
                0.62,
                1709096400
            ],
            [
                0.6619,
                1709182800
            ],
            [
                0.65,
                1709269200
            ],
            [
                0.665,
                1709528400
            ],
            [
                0.679,
                1709614800
            ],
            [
                0.68,
                1709701200
            ],
            [
                0.695,
                1709787600
            ],
            [
                0.7,
                1709874000
            ],
            [
                0.655,
                1710129600
            ],
            [
                0.65,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3614,
        "drug_name": "XPOVIO (selinexor)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Diffuse Large B-Cell Lymphoma (DLBCL)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-06-22",
        "link": "https:\/\/investors.karyopharm.com\/news-releases\/news-release-details\/karyopharm-announces-fda-approval-xpovior-selinexor-treatment",
        "note": "FDA Approval announced June 22, 2020.",
        "company_entity_id": 183,
        "company_ticker": "KPTI",
        "company_name": "Karyopharm Therapeutics Inc.",
        "company_price": "1.4500",
        "company_change": -0.030000000000000027,
        "company_percent_change": -2.0300000000000002,
        "company_optionable": 1,
        "company_number_of_shares": 115067083,
        "price_change_sparkline": [
            [
                0.7505,
                1706677200
            ],
            [
                0.9003,
                1706763600
            ],
            [
                1.04,
                1706850000
            ],
            [
                1.35,
                1707109200
            ],
            [
                1.66,
                1707195600
            ],
            [
                1.525,
                1707282000
            ],
            [
                1.51,
                1707368400
            ],
            [
                1.34,
                1707454800
            ],
            [
                1.3,
                1707714000
            ],
            [
                1.285,
                1707800400
            ],
            [
                1.36,
                1707886800
            ],
            [
                1.3,
                1707973200
            ],
            [
                1.27,
                1708059600
            ],
            [
                1.21,
                1708405200
            ],
            [
                1.21,
                1708491600
            ],
            [
                1.13,
                1708578000
            ],
            [
                1.24,
                1708664400
            ],
            [
                1.31,
                1708923600
            ],
            [
                1.41,
                1709010000
            ],
            [
                1.33,
                1709096400
            ],
            [
                1.16,
                1709182800
            ],
            [
                1.185,
                1709269200
            ],
            [
                1.31,
                1709528400
            ],
            [
                1.245,
                1709614800
            ],
            [
                1.33,
                1709701200
            ],
            [
                1.53,
                1709787600
            ],
            [
                1.57,
                1709874000
            ],
            [
                1.48,
                1710129600
            ],
            [
                1.45,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6772,
        "drug_name": "KEYTRUDA (pembrolizumab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Cutaneous squamous cell carcinoma (cSCC)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-06-24",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20200624005845\/en\/",
        "note": "FDA approval announced June 24, 2020.",
        "company_entity_id": 383,
        "company_ticker": "MRK",
        "company_name": "Merck & Company Inc.",
        "company_price": "122.6600",
        "company_change": -0.10999999999999999,
        "company_percent_change": -0.08999999999999997,
        "company_optionable": 1,
        "company_number_of_shares": 2532643872,
        "price_change_sparkline": [
            [
                120.78,
                1706677200
            ],
            [
                126.38,
                1706763600
            ],
            [
                126.41,
                1706850000
            ],
            [
                126.18,
                1707109200
            ],
            [
                126.88,
                1707195600
            ],
            [
                127.47,
                1707282000
            ],
            [
                126.61,
                1707368400
            ],
            [
                125.45,
                1707454800
            ],
            [
                125.34,
                1707714000
            ],
            [
                125.43,
                1707800400
            ],
            [
                125.82,
                1707886800
            ],
            [
                126.54,
                1707973200
            ],
            [
                127.79,
                1708059600
            ],
            [
                127.37,
                1708405200
            ],
            [
                128.12,
                1708491600
            ],
            [
                129.26,
                1708578000
            ],
            [
                129.45,
                1708664400
            ],
            [
                128.84,
                1708923600
            ],
            [
                129.03,
                1709010000
            ],
            [
                128.19,
                1709096400
            ],
            [
                127.15,
                1709182800
            ],
            [
                126.96,
                1709269200
            ],
            [
                124.05,
                1709528400
            ],
            [
                122.83,
                1709614800
            ],
            [
                123.75,
                1709701200
            ],
            [
                123.99,
                1709787600
            ],
            [
                123.5,
                1709874000
            ],
            [
                122.77,
                1710129600
            ],
            [
                122.66,
                1710216000
            ]
        ],
        "statuses": []
    }
]